pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Nephrology · news · pharmadog
← back to Nephrology
News · Nephrology
282
stories
7h
As part of sales reorganization, Novo will cut 215 employees at US HQ
biospace
1d
Sanofi gains FDA clearance for Gaucher disease pill
biopharma dive
1d
Chutes & Ladders—Teva loses R&D head as innovation pivot advances
fiercebiotech
1d
Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
biospace
1d
STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
stat
1d
Early Alert: Outset Medical Updates Use Instructions for the Tablo Console and the TabloCart with Prefiltration Drawer
fda medwatch
2d
STAT+: Influential preventive services panel to meet for first time in more than a year
stat
2d
GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
biospace
2d
5 acquisitions that forced Big Pharmas to co-parent
biospace
3d
Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
biospace
3d
Scientists uncover ‘very detailed map’ of an enzyme target for rare metabolic disease
fiercebiotech
3d
STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
stat
3d
Kyntra axes mid-stage ADC, adding to years of stumbles
fiercebiotech
4d
BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio
biospace
4d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
8d
STAT+: What to know about Biogen’s big lupus study readout
stat
8d
STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
stat
9d
PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing
biospace
10d
PepGen soars on promising early data for muscular dystrophy drug
biopharma dive
10d
PepGen’s stock doubles as midphase muscle dystrophy data wow analysts
fiercebiotech
11d
FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk
fda press
11d
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
biospace
11d
Novo’s troubled cardio drug could find niche in less sick patients
biospace
11d
Kyorin pens $140M deal for Japan rights to Edesa’s phase 3 respiratory drug
fiercebiotech
11d
MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
fda medwatch
13d
Lowering blood pressure after stroke or with diabetes poses challenges, in research and practice
stat
14d
Moderna enjoys stable vaccine sales thanks to global COVID uptake
biospace
14d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
14d
Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market
biospace
14d
MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
fda medwatch
← prev
page 1 of 10
next →